DPYSL2 interacts with JAK1 to mediate breast cancer cell migration.
Areej Abu RmailehBalakrishnan SolaimuthuAnees KhatibShirel LaviMayur TannaArata HayashiMichal Ben YosefMichal LichtensteinNir PillarYoav David ShaulPublished in: The Journal of cell biology (2022)
The intricate neuronal wiring during development requires cytoskeletal reorganization orchestrated by signaling cues. Because cytoskeletal remodeling is a hallmark of cell migration, we investigated whether metastatic cancer cells exploit axon guidance proteins to migrate. Indeed, in breast cancer patients, we found a significant correlation between mesenchymal markers and the expression of dihydropyrimidinase-like 2 (DPYSL2), a regulator of cytoskeletal dynamics in growing axons. Strikingly, DPYSL2 knockout in mesenchymal-like breast cancer cells profoundly inhibited cell migration, invasion, stemness features, tumor growth rate, and metastasis. Next, we decoded the molecular mechanism underlying this phenomenon and revealed an interaction between DPYSL2 and Janus kinase 1 (JAK1). This binding is crucial for activating signal transducer and activator of transcription 3 (STAT3) and the subsequent expression of vimentin, the promigratory intermediate filament. These findings identify DPYSL2 as a molecular link between oncogenic signaling pathways and cytoskeletal reorganization in migrating breast cancer cells.
Keyphrases
- cell migration
- breast cancer cells
- stem cells
- poor prognosis
- binding protein
- signaling pathway
- transcription factor
- bone marrow
- squamous cell carcinoma
- epithelial mesenchymal transition
- small cell lung cancer
- cell proliferation
- single cell
- dna binding
- young adults
- induced apoptosis
- subarachnoid hemorrhage
- breast cancer risk